InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

Current share price for ATX : $0.130 0.005 (4%)+

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$67 Becoming a substantial holder 14 Jul 2020 12:12PM $0.145 $0.130 fallen by 10.34%
$67 Becoming a substantial holder 14 Jul 2020 11:11AM $0.115 $0.130 risen by 13.04%
$67 Change in substantial holding 14 Jul 2020 10:40AM $0.115 $0.130 risen by 13.04%
$67 Appendix 2A - Institutional Entitlement Offer 10 Jul 2020 4:27PM $0.105 $0.130 risen by 23.81%
$67 Entitlement Offer - Despatch of Retail Offer Booklet 8 Jul 2020 6:03PM $0.115 $0.130 risen by 13.04%
$67 Institutional Entitlement Offer Completed 3 Jul 2020 9:25AM $0.125 $0.130 risen by 4%
$67 Appendix 3B - Rights Issue 1 Jul 2020 1:30PM $0.125 $0.130 risen by 4%
$67 Entitlement Offer Cleansing Notice 1 Jul 2020 10:57AM $0.125 $0.130 risen by 4%
$67 Capital Raising - Investor Presentation 1 Jul 2020 10:55AM $0.125 $0.130 risen by 4%
$67 Entitlement Offer to Fund Phase 1 Clinical Trial 1 Jul 2020 10:54AM $0.125 $0.130 risen by 4%
$67 Trading Halt 1 Jul 2020 10:21AM $0.125 $0.130 risen by 4%
$67 Pause in Trading 1 Jul 2020 9:59AM $0.125 $0.130 risen by 4%
$67 Preliminary Toxicology Studies Support Phase1 Clinical Trial 30 Jun 2020 10:13AM $0.120 $0.130 risen by 8.33%
$67 Trading Halt 29 Jun 2020 9:05AM $0.120 $0.130 risen by 8.33%
$67 Full Year Statutory Accounts - YE 31 March 2020 25 Jun 2020 4:39PM $0.120 $0.130 risen by 8.33%
$67 Investor Presentation 2 Jun 2020 8:49AM $0.140 $0.130 fallen by 7.14%
$67 Preliminary Final Report - YE 31 March 2020 29 May 2020 12:14PM $0.135 $0.130 fallen by 3.70%
$67 FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis 19 May 2020 2:32PM $0.086 $0.130 risen by 51.16%
$67 Quarterly Activities Report - March 2020 Qtr 28 Apr 2020 8:44AM $0.078 $0.130 risen by 66.67%
$67 App 4C - Quarterly Cash Flow Report - March 2020 Qtr 28 Apr 2020 8:41AM $0.078 $0.130 risen by 66.67%
$67 Shares to be Released from Voluntary Escrow 7 Apr 2020 8:55AM $0.056 $0.130 risen by 132.14%
$67 FDA Awards Orphan Drug Designation for Pancreatic Cancer 25 Mar 2020 8:38AM $0.057 $0.130 risen by 128.07%
$67 Professor Paul Timpson Joins Amplia's SAB 13 Feb 2020 8:20AM $0.087 $0.130 risen by 49.43%
$67 Initial Director's Interest Notice - John Lambert 12 Feb 2020 5:07PM $0.087 $0.130 risen by 49.43%
$67 Final Director's Interest Notice - Behrenbruch 7 Feb 2020 4:22PM $0.071 $0.130 risen by 83.10%

426 - 450 of 536 results

Page 18 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.